ReviewFrontiers in immunology2026
From gut microbiota dysbiosis to immune dysregulation: pathogenic mechanisms and emerging therapeutic perspectives in pediatric asthma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric asthma is a chronic inflammatory airway disease with high heterogeneity. Its onset and progression are closely related to environmental exposures in early life and impaired immune regulation. Gut microbiota dysbiosis not only alters the production of metabolites such as short-chain fatty acids, 12,13-diHOME, and succinate, but also drives airway inflammation through multiple immunoregulatory mechanisms. Gut microbial dysbiosis can affect the production of metabolites, such as short-chain fatty acids, and promote airway inflammation through complex immune regulatory mechanisms. In addition, multi-axis interactions, including the gut-brain-lung and gut-bone-lung axis, may influence inflammatory phenotypes and disease heterogeneity in pediatric asthma. This review summarizes the characteristics of gut microbiota dysbiosis in pediatric asthma and focuses on the core mechanisms by which the gut-lung axis contributes to asthma pathogenesis, including metabolite-mediated regulation, disruption of immune homeostasis, mucosal barrier dysfunction, and multi-axis crosstalk. It also summarizes potential intervention approaches targeting the gut microbiota. Elucidating the gut microbiota-immune-multi-organ regulatory network may provide a theoretical basis for the early identification and precision intervention of pediatric asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.